Apollo Neuro Raises $15M Series A To Elevate The First Wellness Wearable That Actively Improves Mental Health

Mar 17, 2022•over 3 years ago

Amount Raised

$15 Million

Round Type

series a

Pittsburgh

Description

Apollo Neuro, makers of the first scientifically validated wearable that improves the body’s resilience to stress, today announced it has raised $15 million in Series A funding at a valuation over $100 million to empower people to take control of their mental health and well-being.

Company Information

Company

Apollo Neuro

Location

Pittsburgh, Pennsylvania, United States

About

Apollo Neuroscience is pioneering new ways to improve mental health by addressing the root of stress and anxiety, the nervous system. The Apollo wearable uses touch therapy to strengthen and rebalance the nervous system, actively improving the body’s resilience to stress. Worn on the wrist or ankle, Apollo's scientifically validated technology sends gentle vibrations to the body that help you feel safe and in control. It’s a simple, unobtrusive tool that trains the nervous system to recover from stress more effectively, without effort on the part of the user. The result? Less stress, more sleep. Less fatigue, more focus. The Apollo wearable is safe for adults and children alike, without side effects. Developed by physicians and neuroscientists, Apollo has been tested in multiple studies and clinical trials and is proven to improve heart rate variability (HRV), a key biometric of stress resilience. For more information, visit apolloneuro.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech